Advanced Therapies – Opportunities and Challenges

R&D and Commercialisation 2020 – Maximising the Value of European Innovation
EBE – a forum for emerging science & innovative technologies

**EBE vision & mission**

*EBE is Europe’s expert voice for emerging bioscience & technology and the leading platform for the health innovation ecosystem.*

We provide an active forum for stakeholder engagement where emerging knowledge and expertise meets and prepares the regulatory and entrepreneurial policies and conditions to accelerate therapeutic innovations to patients.

*EBE is a specialised group of EFPIA.*

**EBE – Partner of choice for biopharma**

- EBE brings together 500+ experts in biopharma product development
- 500+
- Companies representing companies of all sizes (60% of them SME - Mid Cap )
- 50+
- C-level strategy setting board
- C Level
- Financially self-sufficient and sustainable
- Benefits from strong collaboration with key stakeholders at EMA – (CAT, BWP, BMWP), EC, EIB, EIF, patient organisations, investors, medical societies and national biotech associations
EBE Approach

EBE Board – Strategy Setting

EBE team – Execution, support to Working Groups, Task Forces & Networks

- Advanced Therapies*
- Innovation and Funding Models
- Personalised Medicine*
- Biomanufacturing
- Biosimilars/Biotherapeutics
- Cancer Control Task Force
- Allergen Immune Therapy Task Force

Regulatory network / Pharmacovigilance support / Public Affairs network

Value delivery to EBE members

- Connectivity Pharma Biopharma
- European Policy Development
- Biopharma Sector Awareness
- Resources: Information & Training

* Joint WG with EFPIA
The challenge – who is reaping the value of European Innovation?
How is EBE addressing the challenge?
Focus 2017

European Investment Bank
- Feedback on draft report on Financing the EU Life Sciences Sector
- Webinar for EBE members on Financial services

European Parliament
- Workshop “Therapies of the Future”

EU Commission / EMA
- Value of IP and incentives, especially for SMEs
- Industry and joint stakeholder positions on
  - Hospital Exemptions for Advanced Therapies
  - Clinical trials with Advanced Therapies that are or contain GMOs
- Responding to the joint EMA/Commission action plan on Advanced Therapies
- Research on reasons hindering developers of Advanced Therapies – will be released on 5 December

IMI
- Projects that enable pre-competitive aspects of Advanced Therapy development